Chronic Kidney Disease

A randomized study of renin-angiotensin system inhibitors in advanced chronic kidney disease found that patients who continued receiving therapy had similar outcomes to those who discontinued treatment.

Dapagliflozin (Farxiga) found effective in lowering the risk of hospitalization for patients with chronic kidney disease, with or without a diagnosis of type 2 diabetes, and increased the number of days alive and out of the hospital.

Atrasentan has been found to lower albuminuria, which correlates with reductions in low-density lipoprotein cholesterol and triglycerides.

Inhibiting the lipid kinase VPS34 may improve the treatment of diseases such as diabetes and kidney cancer.

Pharmacists play a significant role in the comprehensive management of this condition through education, intervention, and monitoring.

Dapagliflozin and standard of care found to slow the decline in kidney function and lower the incidence of kidney failure.

Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor being evaluated for the treatment of anemia of chronic kidney disease in adult patients on and not on dialysis.

Daprodustat is suggested to improve anemia and quality-of-life in patients with chronic kidney disease.

Active patient care with chronic kidney disease may provide enormous benefits for patients, the economy, and society.

Next-generation research shows that targeting specific Kir channels, which regulate salt reabsorption in the kidneys, could improve diuretic function in kidney patients.

Healthcare practitioner finds that institutions need to acknowledge advantaged and disadvantaged groups of patients as motivation to overcome systemic barriers.

Pharmacists should get out from behind the glass from time to time and work with chronic kidney disease patients to better understand their medications and lifestyle decisions, said an analyst who spoke at ASN Kidney Week in Orlando, Florida.

Researchers outline new findings about the connection between hyperkalemia and renin-angiotensin-aldosterone system inhibitors during a session at ASN Kidney Week.

Applying the principles of precision medicine to peritoneal dialysis could improve the flexibility and personalization of care for dialysis patients.

Education, awareness, and more training may help more pharmacists and kidney patients consider home dialysis as an effective treatment option, said an expert on November 4 at ASN Kidney Week in Orlando, Florida.

Researcher suggests that medications for high blood pressure may be useful in treating patients with slow-onset immunoglobulin A nephropathy, a topic he will present on this weekend at ASN Kidney Week in Orlando, Florida.

Daniel Weiner, MD, MS, associate professor at Tufts University, discusses effective treatment approaches for diabetic kidney disease at ASN Kidney Week.

It may be worth considering the pathophysiology and vascular complications of chemotherapy, especially among patients who are already hypertensive.

The drug is a selective, nonsteroidal mineralocorticoid receptor antagonist found to also protect against COVID-19 and pneumonia-related adverse events in patients with diabetes.

Pharmacy Times will be covering the American Society of Nephrology (ASN) Kidney Week, which will be gathering more than 10,000 professionals working on kidney health in Orlando, Florida.

Pharmacy Times is gearing up for Kidney Week (Nov. 3-6) by learning about the pharmacological role of kidney care from the president of the American Society of Nephrology.

The estimation of glomerular filtration rate based on cystatin C could provide a more robust prediction of cardiovascular disease and mortality in patients.

The objective of the trial was to compare letermovir with valganciclovir in preventing CMV disease in adults who received a kidney transplant and who are at high risk for CMV disease.

SGLT-2 inhibitors, GLP-1 receptor agonists, and a non-steroidal mineralocorticoid receptor are all showing promise in the prevention and management of diabetic kidney disease.

New research suggests that high levels of an immune protein in kidney disease might be able to predict risk of heart failure or death by reflecting the upstream process of stress.

The study confirmed that patients with psoriasis are considered to have an increased risk for both chronic kidney disease and ESRD, because inflammation plays a significant role in those conditions as well as heart disease.

Panelists at the AMCP Nexus conference discuss the burden of undertreated and untreated chronic kidney disease.

Although survival benefits for patients who received a kidney transplant varied, the benefits of kidney transplants were greater for all patients when compared with long-term dialysis.

Understanding long-term frailty trajectories with kidney function measures could help prevent worse adverse health outcomes in older patients.

Investigators combine research discovery with technological development to determine whether the role of genomics in nephrology should remain with subspecialists or be integrated into general nephrology.